Univariable and multivariable Cox analysis for discontinuation of fixed-dose combination therapy
| Univariable | Multivariable | |||
| HR (95% CI) | p Value | HR (95% CI) | p Value | |
| Types of FDC | ||||
| CCB and statin | 1 (Reference) | – | – | |
| CCB and ARB | 1.009 (0.699 to 1.458) | 0.960 | ||
| ARB and diuretics | 0.747 (0.527 to 1.059) | 0.101 | ||
| ASCVD risk scores, % | 0.981 (0.972 to 0.989) | <0.001 | 0.984 (0.975 to 0.990) | 0.003 |
| Tertiles of the numbers of conventional risk factors* | ||||
| Lower tertile | 1 (Reference) | – | 1 (Reference) | – |
| Mid tertile | 0.430 (0.316 to 0.586) | <0.001 | 0.432 (0.314 to 0.593) | <0.001 |
| Upper tertile | 0.113 (0.174 to 0.173) | <0.001 | 0.114 (0.072 to 0.179) | <0.001 |
*Conventional risk factors include age, body mass index, systolic blood pressure, total cholesterol, triglycerides, HDL cholesterol, LDL cholesterol, fasting glucose, creatinine, smoking, alcohol, heart failure, dyslipidaemia, diabetes mellitus, hypertension, ischaemic heart disease, stroke, peripheral vascular disease, chronic renal replacement therapy, and family history of premature coronary heart disease.
ARB, angiotensin receptor blocker; ASCVD, atherosclerotic cardiovascular disease; CCB, calcium channel blocker; FDC, fixed-dose combination; lower tertile, ≤4 risk numbers; 5 ≤ mid-tertile, ≤7 risk numbers; upper tertile, ≥8 risk numbers.